
Our Management and Advisory Team
Oncometa understands that its success is based on unique products as well as the management of its business. The Company is determined to attract highly talented professionals to become part of the Oncometa team.
Oncometa believes in conducting its business efficiently and effectively. The company's goal is to make sure that every step of the way leads to financial success for it's shareholders. The company is also aggressively recruiting the best advisors to help with its development, operation and management.
Oncometa understands that its success is based on unique products as well as the management of its business. The Company is determined to attract highly talented professionals to become part of the Oncometa team.
- Yeh-Bin Wu MD, Chairman of the Board
- President of Arjil Investment Partnership
- Board of directors at Precise Power Corporation
- Chairman of Zaitech Capital Corporation
- Brandon J. Price PhD, Chief Executive Officer
- Acting CEO, GalenBio, Inc.
- Former CEO, Cognate Therapeutics, Goodwin Biotechnology, CropTech
- Member of road show team for successful BioReliance IPO (Morgan-Stanley and H&Q)
- Consultant to 40+ start-up and $Bn+ companies (all life sciences) on business planning, manufacturing, marketing and selling strategies
- James Chan MD, Chief Science Officer
- Inventor of ON drugs
- Research conducted in private laboratories
- Alice TC Chen, CPA, MBA, Chief Financial Officer (CFO)
- Former International Tax Manager, Ernst & Young
- Former Financial Analyst, Goldman Sachs and Lehman Brothers
- Former Accounting Instructor, CUNY/Baruch College
- Shutsung Liao, PhD
- Professor, Ben May Department for Cancer Research, University of Chicago
- Nobel Prize Nominee
- Aaron Vinik, MD, PhD, FCP, FACP
- Director, Strelitz Diabetes Research Center
- Scientific Director, Department of Medicine
- Professor of Medicine, Eastern Virginia Medical School
- Frank L. Greenway, MD
- Medical Director and Professor, Pennington Biomedical Research Center, Louisiana State University, Baton Rouge
- FDA Endocrinologic and Metabolic Drugs Advisory Committee Member
- North American Association for the Study of Obesity, Clinical Counselor
- Sien-Sing Yang, MD
- Director, Liver Unit, Cathay General Hospital
- Chief of Gastroenterology, Fu-Jen Catholic University
- Board of Directors, Taiwan Liver Cancer Society
- Richard Atkinson, MD
- Clinical Professor of Pathology, Virginia Commonwealth University School of Medicine
- Director, Obetech Obesity Research Center; President, Obetech, LLC
- Co-founder and former President, American Obesity Association
- Editor, International Journal of Obesity
- Eugene Woltering, MD, FACS
- Section Chief of Surgical Oncology & Endocrine Surgery, Louisiana State University Health Sciences Center, New Orleans
- The James D. Rives Professor of Surgery and Neuroscience
- Director of Surgical Research
- Kuan Zhang, PhD
- Director, Human Energy Expenditure Core, Obesity Research Center, St. Luke's-Roosevelt Hospital Center at Columbia University
- Assistant Professor, Columbia University College of Physicians and Surgeons
- Joseph Vasselli, PhD
- Associate Research Scientist, Columbia University Institute of Human Nutrition, NYC
- Coordinator, Department of Medicine Endocrine-Metabolic Research Conference, St. Luke's-Roosevelt Hospital Center
- Member, Neurobiology Research Group, Departments of Biology and Psychology, Columbia University and Barnard College
- Grant Williams, MD
- Former FDA Oncology Drugs Deputy Director with 16 years experience in Oncology Review at FDA
- Former PhRMA Oncology Clinical Development at Novartis and GSK
- Linda Bavisotto, MD
- Former Assistant Professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine, Seattle
- Former Member, Medical Staff, University of Washington Medical Center
- Former Principal Investigator, Charles River Laboratories Clinical Services
Oncometa believes in conducting its business efficiently and effectively. The company's goal is to make sure that every step of the way leads to financial success for it's shareholders. The company is also aggressively recruiting the best advisors to help with its development, operation and management.
